Loading...
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
Relapsed Hodgkin lymphoma remains a clinical challenge, with few non-cytotoxic treatment options. CD80 is a surface antigen that normally functions as a co-stimulatory molecule but is aberrantly and uniformly expressed on Reed–Sternberg cells. Galiximab is a primatized monoclonal antibody against CD...
Saved in:
| Published in: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499151/ https://ncbi.nlm.nih.gov/pubmed/23194022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.744453 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|